Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
1995-06-07
2002-06-11
Gambel, Phillip (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S133100, C424S141100, C424S143100, C424S144100, C424S153100, C424S173100, C530S388700, C530S388730, C530S388750, C435S343000, C435S343100, C435S343200
Reexamination Certificate
active
06403091
ABSTRACT:
BACKGROUND OF THE INVENTION
Throughout this application, various publications are referenced by Arabic numerals within parenthesis. Full citations for these publications may be found at the end of the specification, immediately preceding the claims. The disclosures of these publications are hereby incorporated by reference into this application in order to more full describe the state of the art as known to one skilled therein as of the date of the invention described and claimed herein.
In a contact-dependent process termed “T cell helper function,” CD4
+
T lymphocytes direct the activation and differentiation of B lymphocytes and thereby regulate the humoral immune response by modulating the specificity, secretion and isotype-encoded functions of antibody molecules (1-8). The T cell surface molecules that mediate the contact-dependent elements of T cell helper function are not yet fully known (9).
The process by which T cells help B cells to differentiate has been divided into two distinct phases: the inductive and effector phases (10,11). In the inductive phase, resting T cells contact antigen-primed B cells and this association allows clonotypic T cell receptor (TCR)-CD4 complexes to interact with Ia/Ag complexes on B cells (5, 12-19).
TCR/CD4 recognition of Ia/Ag results in the formation of stable T-B cognate pairs and bidirectional T and B cell activation (20-26). In the effector phase, activated T cells drive B cell differentiation by secreting lymphokines (27-30) and by contact-dependent stimuli (24, 31-38), both of which are required for T cells to drive small, resting B cells to terminally differentiate into Ig secreting cells (31, 39-42).
Although the inductive phase of T cell help is Ag-dependent and MHC-restricted (5, 12-18, 40), the effector phase of T cell helper function can be Ag-independent and MHC-nonrestricted (31, 34, 36, 40, 43-50). An additional contrasting feature is that the inductive phase of T cell help often requires CD4 molecules and is inhibited by anti-CD4 mAb (19), whereas helper effector function does not require CD4 molecules (51) and is not inhibited by anti-CD4 mAbs (33, 34, 36, 49). The nonspecific helper effector function is believed to be focused on specific B cell targets by the localized nature of the T-B cell interactions with antigen specific, cognate pairs (25, 26, 52).
Although terminal B cell differentiation requires both contact- and lymphokine-mediated stimuli from T cells, intermediate stages of B cell differentiation can be induced by activated T cell surfaces in the absence of secreted factors (32, 33, 53-56). These intermediate effects on B cells include induction of surface CD23 expression (32, 35, 57), enzymes associated with cell cycle progression (37) and responsiveness to lymphokines (24, 37, 49, 54-56). Although the activation-induced T cell surface molecules that direct B cell activation have not been previously identified, functional studies have characterized some features of their induction and biochemistry. First, T cells acquire the ability to stimulate B cells 4-8 h following activation (38, 49). Second, the B cell stimulatory activity associated with the surfaces of activated T cells is preserved on paraformaldehyde fixed cells (24, 32, 37, 49, 56) and on purified membrane fragments (33, 53-55). Third, the B cell stimulatory activity is sensitive to protease treatment (24, 53, 54). Fourth, the process of acquiring these surface active structures following T cell activation is inhibited by cycloheximide (49, 54). Although these studies strongly suggest the existence of activation-induced T cell surface proteins that deliver contact dependent stimuli to B cells, the molecular identities of such structures have not previously been described.
SUMMARY OF THE INVENTION
This invention provides a monoclonal antibody which specifically recognizes and forms a complex with T-B cell activating molecule (T-BAM) (now also known as CD40 ligand) a protein located on the surface of activated T cells and thereby inhibits T cell activation of B cells. This invention also provides the monoclonal antibody 5c8 (ATCC Accession No. HB 10916).
This invention provides a human CD4
−
T cell leukemia cell line designated D1.1 (ATCC Accession No. CRL 10915) capable of constitutively providing contact-dependent helper function to B cells. This invention also provides an isolated protein from the surface of activated T cells, wherein the protein is necessary for T cell activation of B cells. This invention further provides an isolated, soluble protein from the surface of activated T cells, wherein the protein is necessary for T cell activation of B cells.
Monoclonal antibody 5c8 and a human CD4− T-Cell line, designated, D1.1 have been deposited on Nov. 14, 1991 with the American Type Culture Collection, 10801 University Blvd., Manassas, Va., 20110-2209, U.S.A., pursuant to the provisions of the Budapest Treaty on the International Recognition of the Microorganism Deposit for the Purposes of Patent Procedure and have been accorded ATCC Nos. HB 10916 and CRL 10915, respectively.
REFERENCES:
patent: 5683693 (1997-11-01), Noelle et al.
patent: 5961974 (1999-10-01), Armitage et al.
patent: 9007861 (1990-07-01), None
patent: 9308207 (1993-04-01), None
patent: WO9506480 (1995-03-01), None
patent: WO9623071 (1996-08-01), None
patent: WO9830240 (1998-07-01), None
patent: WO9830241 (1998-07-01), None
Tufveson et al. Immunol. Reviews 136: 99-109 (1993).*
Wee et al. Transplantation 58: 261-264 (1994).*
Seachrist Bioworld Today 10(204):1,3 10/25/99.*
Stuber et al. J Exp Med 183: 693-698.*
Gray et al. J Exp Med 180: 141-155 (1994).*
Larsen et al. Transplantation 61: 4-9 (1996).*
Biacone et al. Kidney Intl. 48: 458-468 (1995).*
Magee et al. Therapeutic Immunology 1: 45-58 (1994).*
Noelle Immunity 4: 415-419 (1996).*
Paul (Ed) Fundamental Immunology 3rdEd. Raven Press 1993 p. 242 only.*
Press Release from Biogen, Inc., dated Oct. 21, 1999, “Biogen Says It Has Halted Several Trials of Anti-CD40 Ligand Monoclonal Antibody” (Exhibit A).
Press Release from Biogen, Inc., dated Nov. 2, 1999, “Biogen Says It has Stopped Ongoing Trials of anti-CD40 Ligand Monoclonal Antibody” (Exhibit B).
Durie, F., et al., (Sep. 3, 1993) “Prevention of Collagen-induced arthritis with an antibody to gp39, the ligand for CD40” Science 261(5126): 1328-1330 (Exhibit J).
Gerriste, K., et al., (Mar. 19, 1996) “CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis.” PNAS USA 93(6): 2499-2504 (Exhibit K).
Early, G., et al. (Oct. 1, 1996) “Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black x New Zealand white mice.” J. Immunology 157(7): 3159-3164(Exhibit L).
Potocnik, A.J., et al. (1990) Scand. J. Immunol. 31: 213-224(Exhibit M).
R.J. Armitage, et al.,Nature(1992) 357:80-82.
P. Lane, et al.,Eur. J. Immunol.(1992) 22:2573-2578.
L.S. Marshall and R.J. Noelle,FASEB J.(1991) 5(4):A608; Abstract No. 1379.
R.J. Noelle, et al.,Proc. Natl. Acad. Sci USA(1992) 89:6550-6554.
R.J. Noelle, et al.,Immunol. Today(1992) 13(11):431-433.
R.J. Noelle and E.C. Snow,FASEB J.(1991) 5(13):2770-2776.
R. Noelle and C.E. Snow,Current Opinion in Immunology(1992) 333-337.
R.J. Noelle, et al. inMechanisms of Lymphocyte Activation and Immune Regulation IV: Cellular Communications,S. Gupta and T.A. Waldmann, eds. (Plenum, New York 1992) 131-137.
Waldmann, T.A.,Science(1991) 252:1657-1662.
Cunningham, C., et al.,TIBTECH(1992) vol. 10: 112-113.
Rogozinski, et al.,J. Immunol.(1984) 132:735-739.
Dillman, R.O.,Annals Int. Med.(1989) 111:592-603.
Weiss, et al.,Adv. Immunol.(1987) 41:1-38.
Harris, W., et al.,TIBTECH(1993) 11:42-44.
Lederman, et al.,J. Exp. Med.(1992) 175:1091-1101.
Joliffe, L.K.,Intern. Rev. Immunol.(1993) 10:241-250.
Borrebaeck, C.A.K., et al.,Immunol. Today(1993) 14:477-482.
Kahan, B.,Current Opin. Immunol.(1992) 4:553-560.
Tueveson, G., et al.,Immunol. Rev.(1993) Issue No. 136:99-109.
Emery, S.C., et al.,Exp. Opin. Invest. Drugs(1994) 3:241-251.
Winter, G., et al.,TIPS(1993) 14:
Chess Leonard
Lederman Seth
Yellin Michael J.
Cooper & Dunham LLP
Gambel Phillip
The Trustees of Columbia University in the City of New York
White John P.
LandOfFree
Methods for inhibiting the rejection of a transplant organ... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for inhibiting the rejection of a transplant organ..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for inhibiting the rejection of a transplant organ... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2920694